The Indian Rotavirus Vaccine Development Project (RVDP) announced that the results from the recent Phase I clinical trials of two candidate rotavirus vaccines - 116E and I321 - were encouraging. RVDP has the department of biotech, Bharat Biotech, Society for Advanced Studies, New Delhi, Centres for Disease Control, Atlanta, GA, National Institutes of Health, the Indian Institute of Science and Stanford University as members. Following phase I trial, RVDP plans trials with cGMP vaccines of Bharat Biotech, using same strains.